SCHEMBL3275527

SCHEMBL3275527

Cn1cnc(S(=O)(=O)N(Cc2ccccc2)c2ccc(C(=O)N3CCN(c4ccccc4F)CC3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
KDM4E B2RXH2 1/20 0.49
ALOX15 P16050 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.48
HTT P42858 2/20 0.48
KMT2A Q03164 3/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 1/20 0.47
MEN1 O00255 2/20 0.46
POLB P06746 2/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL304469 0.91 LMNA (0.48) LMNAKDM4EALOX15SMN1; SMN2HTT
SCHEMBL3376397 0.91 KMT2A (0.50) LMNAKDM4EALOX15SMN1; SMN2HTT
SCHEMBL1722406 0.89 LMNA (0.58) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL303692 0.88 LMNA (0.66) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL1725046 0.85 LMNA (0.54) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL3274787 0.84 LMNA (0.52) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL1723243 0.84 LMNA (0.54) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL302045 0.84 SLC6A7 (0.53) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL303115 0.83 LMNA (0.52) LMNASMN1; SMN2HTTKMT2AHPGD
SCHEMBL302272 0.81 KMT2A (0.51) LMNAKDM4ESMN1; SMN2HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885KDM4E 587/4885ALOX15 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.